Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

Firm News

WilmerHale client Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced the pricing of a registered underwritten public offering of 3,902,439 shares of its common stock at a price to the public of $10.25 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $40 million.

The WilmerHale deal team representing Karyopharm includes Steven Singer, Jason Kropp, Craig Hilts and Alex Civetta.

Read Karyopharm Therapeutics' press release for more information. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.